“GlycosBio is a smart company making incredible discoveries to help further the industry’s advancement toward biochemical independence." Gary Mossman, Glycos Biotechnologies Board Member
Houston, TX (PRWEB) February 10, 2011
Glycos Biotechnologies, Inc. (GlycosBio), an international biochemical company commercializing advanced metabolic engineering and microbial strain processes to convert low-value feedstocks into high-value sustainable chemicals, today announced the appointment of Gary Mossman, chemical industry veteran, to the Company’s Board of Directors. Mossman’s experience spans both large and small molecular technology with more than 40 years of executive management and investment responsibility in private and public pharmaceutical and specialty chemical firms.
“GlycosBio is very pleased to welcome Gary to our Board of Directors,” said Richard Cilento, Chief Executive Officer of Glycos Biotechnologies. “Gary’s range of expertise in chemicals, pharmaceuticals and manufacturing coupled with his business, technical and leadership background will play an integral role in GlycosBio’s efforts to continue developing innovative products and further advance the Company’s position as a leader in producing sustainable biochemicals.”
Mossman is currently Chief Operating Officer (COO) and Director of PLx Pharma, an emerging Pharma company and Chairman of Redline Industries, a metal fabricator. In addition, he is a director of the Nassau Bay Economical Development Council and the CCISD Educational Foundation. Previously, Mossman held the position of Executive Vice President and COO of Cambrex Corporation where he was responsible for global operations of this leading provider of API’s including Generics, Biotech and Pharma Development Services, Drug Delivery, and Diagnostic Products. Mossman also served as Chief Executive Officer and Vice Chairman of Dixie Chemical Company, a top tier specialty chemical company.
“The majority of my professional career has been focused in specialty chemicals, biotechnology and biopharmaceuticals,” said Mossman. “GlycosBio is a smart company making incredible discoveries to help further the industry’s advancement toward biochemical independence and I’m excited to have the opportunity to extend my experience and knowledge to GlycosBio to help them continue to reach their business goals.”
Mossman joins current GlycosBio Board of Directors members including Walter Burnap, President and Chief Financial Officer of GlycosBio; Richard Cilento, Chief Executive Officer of GlycosBio; Steve Jurvetson, Managing Director, Draper Fisher Jurvetson; and Dan Watkins, Managing Director of DFJ Mercury.
About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (“GlycosBio”) is an international biochemical company commercializing advanced metabolic engineering and microbial strain processes that convert multiple low value feedstocks into a range of high value sustainable chemicals. By designing a portfolio of differentiated microorganisms, GlycosBio’s bioconversion technology produces a diverse set of chemicals, including substitutes for fossil fuel derived petrochemicals, meeting the growing global demand for clean, environmentally safe biochemicals.
GlycosBio is privately held and focused on biochemical commercialization and production with established global partnerships including relationships with petrochemical companies to secure low cost, non-petroleum based chemicals. For more information, visit http://www.glycosbio.com.